{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:14:56Z","timestamp":1760145296591,"version":"build-2065373602"},"reference-count":41,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2024,6,30]],"date-time":"2024-06-30T00:00:00Z","timestamp":1719705600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"the Universidad Peruana Union"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Hepatitis C virus still represents a major cause of morbidity and mortality worldwide. In Peru, two national practice guidelines for the management of this infection were published more than 5 years ago; however, the latest breakthroughs in the treatment make it necessary to update these guidelines. We reviewed the most recent recommendations of the international guidelines and compared them with the current Peruvian guidelines. We found major differences, such as the use of Glecaprevir\/Pibrentasvir as a first-line therapy, which is contemplated in the World Health Organization guideline, and recommended by American and European guidelines, but is not considered in the Peruvian guidelines. Another crucial difference lies in the management of patients with chronic kidney disease, who are treated nowadays with a variety of direct-acting antivirals, with no restrictions on the use of Sofosbuvir-based regimens in first-world countries, an approach that has not been adopted in Peru. We believe that standardization of the recommendations of the Peruvian guidelines is imperative, including the new therapeutic strategies that have emerged in recent years. We also suggest conducting a cost effectiveness analysis in the Peruvian context to allow for the implementation of new antivirals, and to achieve a better control of hepatitis C in the country.<\/jats:p>","DOI":"10.3390\/jcm13133867","type":"journal-article","created":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T09:06:07Z","timestamp":1719824767000},"page":"3867","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Identifying Gaps in the Treatment Guidelines for Hepatitis C in Peru to Meet International Standards: A Narrative Review"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2768-9712","authenticated-orcid":false,"given":"Jose A.","family":"Gonzales-Zamora","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Miller School of Medicine, University of Miami, Miami, FL 33136, USA"},{"name":"Peruvian American Medical Society (PAMS), Albuquerque, NM 87111, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0076-0985","authenticated-orcid":false,"given":"Carlos","family":"Quispe-Vicu\u00f1a","sequence":"additional","affiliation":[{"name":"Red de Eficacia Cl\u00ednica y Sanitaria (REDECS), Lima 15048, Peru"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mart\u00edn E.","family":"Reategui-Garcia","sequence":"additional","affiliation":[{"name":"School of Medicine, Universidad Nacional de la Amazon\u00eda Peruana, Iquitos 16000, Peru"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0267-8942","authenticated-orcid":false,"given":"Julieta M.","family":"Araoz-Salinas","sequence":"additional","affiliation":[{"name":"Peruvian American Medical Society (PAMS), Albuquerque, NM 87111, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3172-2113","authenticated-orcid":false,"given":"Fabricio","family":"Ccami-Bernal","sequence":"additional","affiliation":[{"name":"School of Medicine, Universidad Nacional de San Agust\u00edn de Arequipa, Arequipa 04001, Peru"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noelia","family":"Morocho-Alburqueque","sequence":"additional","affiliation":[{"name":"School of Medicine, Universidad Nacional de Piura, Piura 200104, Peru"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian Pierre","family":"Espinoza-Herreros","sequence":"additional","affiliation":[{"name":"School of Medicine, Universidad Privada Antenor Orrego, La Libertad 13006, Peru"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josue","family":"Layme","sequence":"additional","affiliation":[{"name":"Peruvian American Medical Society (PAMS), Albuquerque, NM 87111, USA"},{"name":"School of Medicine, Universidad Nacional Mayor de San Marcos, Lima 15001, Peru"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0107-4356","authenticated-orcid":false,"given":"Gabriel","family":"Aquino-Sandoval","sequence":"additional","affiliation":[{"name":"School of Medicine, Universidad Nacional de la Amazon\u00eda Peruana, Iquitos 16000, Peru"},{"name":"Sociedad Cient\u00edfica de Estudiantes de Medicina de la Amazon\u00eda Peruana (SOCIEMAP), Universidad Nacional de la Amazon\u00eda Peruana, Iquitos 16000, Peru"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0408-7249","authenticated-orcid":false,"given":"Victor Y. Melt","family":"Campos","sequence":"additional","affiliation":[{"name":"Peruvian American Medical Society (PAMS), Albuquerque, NM 87111, USA"},{"name":"Department of Community Health and Family Medicine, College of Medicine, University of Florida, Jacksonville, FL 32209, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1178-2445","authenticated-orcid":false,"given":"Jorge","family":"Alave","sequence":"additional","affiliation":[{"name":"School of Medicine, Universidad Peruana Union, Lima 15464, Peru"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,6,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Yang, J., Qi, J.-L., Wang, X.-X., Li, X.-H., Jin, R., Liu, B.-Y., Liu, H.-X., and Rao, H.-Y. (2023). The Burden of Hepatitis C Virus in the World, China, India, and the United States from 1990 to 2019. Front. Public Health, 11.","DOI":"10.3389\/fpubh.2023.1041201"},{"key":"ref_2","unstructured":"World Health Organization (2024, May 02). Global Hepatitis Report 2024: Action for Access in Low- and Middle-Income Countries. Available online: https:\/\/www.who.int\/publications-detail-redirect\/9789240091672."},{"key":"ref_3","unstructured":"World Health Organization (2024, April 05). Hepatitis. Available online: https:\/\/www.who.int\/health-topics\/hepatitis\/elimination-of-hepatitis-by-2030#tab=tab_1."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","article-title":"Global Prevalence and Genotype Distribution of Hepatitis C Virus Infection in 2015: A Modelling Study","volume":"2","author":"Blach","year":"2017","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"164","DOI":"10.47892\/rgp.2021.413.1246","article-title":"Prevalence of viral hepatitis type C in blood donors in Peru 2016\u20132017","volume":"41","author":"Bellido","year":"2021","journal-title":"Rev. Gastroenterol. Peru"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/cld.1084","article-title":"Hepatitis C Virus Infection: What Are We Currently Doing in Latin America About WHO\u2019s Proposals for 2030?","volume":"18","author":"Roblero","year":"2021","journal-title":"Clin. Liver Dis."},{"key":"ref_7","first-page":"s243","article-title":"Sistema de salud de Per\u00fa","volume":"53","author":"Nigenda","year":"2011","journal-title":"Salud Publica Mex."},{"key":"ref_8","unstructured":"Ministerio de Salud del Per\u00fa (2024, May 02). Norma T\u00e9cnica de Salud para la Prevenci\u00f3n, Diagn\u00f3stico y Tratamiento de la Hepatitis Viral C en el Per\u00fa. Available online: https:\/\/www.gob.pe\/institucion\/minsa\/normas-legales\/235205-1317-2018-minsa."},{"key":"ref_9","unstructured":"(2024, May 02). Seguro Social de Salud-ESSALUD. Gu\u00eda de Pr\u00e1ctica Cl\u00ednica para el Diagn\u00f3stico y Tratamiento de la Infecci\u00f3n Cr\u00f3nica Por el Virus de la Hepatitis (2019)-GPC. Available online: https:\/\/gpc-peru.com\/gpchvc."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"141","DOI":"10.47892\/rgp.2022.422.1360","article-title":"Tratamiento de Hepatitis C Cr\u00f3nica En Pacientes Con Enfermedad Renal: Aportes a La Gu\u00eda de Pr\u00e1ctica Cl\u00ednica Del Seguro Social de Salud Del Per\u00fa (EsSalud)","volume":"42","author":"Alave","year":"2022","journal-title":"Rev. Gastroenterol. Peru"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Suthar, A.B., and Harries, A.D. (2015). A Public Health Approach to Hepatitis C Control in Low- and Middle-Income Countries. PLoS Med., 12.","DOI":"10.1371\/journal.pmed.1001795"},{"key":"ref_12","unstructured":"World Health Organization (2024, May 02). Guidelines for the Care and Treatment of Persons Diagnosed with Chronic Hepatitis C Virus Infection. Available online: https:\/\/www.who.int\/publications-detail-redirect\/9789241550345."},{"key":"ref_13","unstructured":"American Association for the Study of Liver Diseases, and Infectious Diseases Society of America (2024, May 02). HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. Available online: https:\/\/www.hcvguidelines.org\/."},{"key":"ref_14","unstructured":"European Association for the Study of the Liver, Clinical Practice Guidelines Panel, EASL Governing Board Representative, and Panel Members (2020). EASL Recommendations on Treatment of Hepatitis C: Final Update of the Series\u2606. J. Hepatol., 73, 1170\u20131218."},{"key":"ref_15","unstructured":"EsSalud Per\u00fa (2024, April 05). Hospital Rebagliati Cuenta Con Moderno M\u00e9todo de Elastograf\u00eda Por Vibraci\u00f3n Controlada Para Evaluar Enfermedades del H\u00edgado. Available online: http:\/\/noticias.essalud.gob.pe\/?inno-noticia=hospital-rebagliati-cuenta-con-moderno-metodo-de-elastografia-por-vibracion-controlada-para-evaluar-enfermedades-del-higado."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"S589","DOI":"10.1016\/S0168-8278(15)30912-0","article-title":"P0709: Survival of Patients Infected by Chronic Hepatitis C and F0F1 Fibrosis at Baseline after a 15 Year Follow-Up","volume":"62","author":"Jezequel","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Zahnd, C., Salazar-Vizcaya, L.P., Dufour, J.F., Mullhaupt, B., Wandeler, G., Kouyos, R., Bertisch, B., Rauch, A., and Keiser, O. (2015, January 23\u201326). Impact of Deferring HCV Treatment on Liver-Related Events in HIV+ Patients. Proceedings of the Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, WA, USA.","DOI":"10.1016\/j.jhep.2016.02.030"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Roguljic, H., Nincevic, V., Bojanic, K., Kuna, L., Smolic, R., Vcev, A., Primorac, D., Vceva, A., Wu, G.Y., and Smolic, M. (2021). Impact of DAA Treatment on Cardiovascular Disease Risk in Chronic HCV Infection: An Update. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.678546"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1111\/dom.14168","article-title":"Reduced Incidence of Type 2 Diabetes in Patients with Chronic Hepatitis C Virus Infection Cleared by Direct-Acting Antiviral Therapy: A Prospective Study","volume":"22","author":"Adinolfi","year":"2020","journal-title":"Diabetes Obes. Metab."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","article-title":"Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection","volume":"373","author":"Feld","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1111\/liv.14537","article-title":"Global Real-World Evidence of Sofosbuvir\/Velpatasvir as Simple, Effective HCV Treatment: Analysis of 5552 Patients from 12 Cohorts","volume":"40","author":"Mangia","year":"2020","journal-title":"Liver Int."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jhep.2018.03.007","article-title":"High SVR12 with 8-Week and 12-Week Glecaprevir\/Pibrentasvir Therapy: An Integrated Analysis of HCV Genotype 1\u20136 Patients without Cirrhosis","volume":"69","author":"Puoti","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.jhep.2019.10.020","article-title":"Glecaprevir\/Pibrentasvir for 8 Weeks in Treatment-Na\u00efve Patients with Chronic HCV Genotypes 1\u20136 and Compensated Cirrhosis: The EXPEDITION-8 Trial","volume":"72","author":"Brown","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.jhep.2020.01.025","article-title":"Real-World Effectiveness and Safety of Glecaprevir\/Pibrentasvir for the Treatment of Patients with Chronic HCV Infection: A Meta-Analysis","volume":"72","author":"Lampertico","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1053\/j.gastro.2015.05.010","article-title":"SOLAR-1 Investigators. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients with Advanced Liver Disease","volume":"149","author":"Charlton","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1056\/NEJMoa1704053","article-title":"Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment","volume":"377","author":"Gane","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1111\/liv.14320","article-title":"Efficacy and Safety of Glecaprevir\/Pibrentasvir in Renally Impaired Patients with Chronic HCV Infection","volume":"40","author":"Lawitz","year":"2020","journal-title":"Liver Int."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s40262-015-0261-7","article-title":"Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of the Hepatitis C Virus NS5B Polymerase Inhibitor Sofosbuvir","volume":"54","author":"Kirby","year":"2015","journal-title":"Clin. Pharmacokinet."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1177\/1756283X13515825","article-title":"Sofosbuvir, a NS5B Polymerase Inhibitor in the Treatment of Hepatitis C: A Review of Its Clinical Potential","volume":"7","author":"Stedman","year":"2014","journal-title":"Therap. Adv. Gastroenterol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1111\/apt.16830","article-title":"Sofosbuvir and Risk of Estimated Glomerular Filtration Rate Decline or End-Stage Renal Disease in Patients with Renal Impairment","volume":"55","author":"Sulkowski","year":"2022","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_31","unstructured":"HEALIO (2024, May 02). Gilead DAAs Safe, Effective for Adults with HCV, Severe Renal Impairment. Available online: https:\/\/www.healio.com\/news\/hepatology\/20191121\/gilead-daas-safe-effective-for-adults-with-hcv-severe-renal-impairment."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.jhep.2019.05.028","article-title":"Sofosbuvir\/Velpatasvir for 12 weeks in Hepatitis C Virus-Infected Patients with End-Stage Renal Disease Undergoing Dialysis","volume":"71","author":"Borgia","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.jhep.2017.01.007","article-title":"NS5A Resistance-Associated Substitutions in Patients with Genotype 1 Hepatitis C Virus: Prevalence and Effect on Treatment Outcome","volume":"66","author":"Zeuzem","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_34","unstructured":"Thompson, A., Stefan, Z., Rockstroh, J.K., Kwo, P.Y., Roth, D., Lawitz, E.J., Sulkowski, M.S., Forns, X., Wahl, J., and Nguyen, B. (2015, January 13\u201317). The Combination of Grazoprevir and Elbasvir +RBV Is Highly Effective for the Treatment of GT1a-Infected Patients. Proceedings of the The Liver Meeting 2015, San Francisco, CA, USA."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1002\/hep.30046","article-title":"Glecaprevir\/Pibrentasvir Treatment in Liver or Kidney Transplant Patients with Hepatitis C Virus Infection","volume":"68","author":"Reau","year":"2018","journal-title":"Hepatology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"109","DOI":"10.7326\/M16-1205","article-title":"Treatment with Ledipasvir-Sofosbuvir for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic Hepatitis C Virus Genotype 1 or 4 Infection: A Randomized Trial","volume":"166","author":"Colombo","year":"2017","journal-title":"Ann. Intern. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s12325-019-01166-3","article-title":"A Cost-Effectiveness Analysis of Glecaprevir\/Pibrentasvir Versus Existing Direct-Acting Antivirals to Treat Chronic Hepatitis C in Japan","volume":"37","author":"Kawaguchi","year":"2020","journal-title":"Adv. Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s40121-024-00926-1","article-title":"Direct-Acting Antivirals Remain Cost-Effective Treatments for Chronic Hepatitis C in Australia Despite Changes to the Treated Population and the Availability of Retreatment: The Glecaprevir\/Pibrentasvir (Maviret\u00ae) Example","volume":"13","author":"Warren","year":"2024","journal-title":"Infect. Dis. Ther."},{"key":"ref_39","unstructured":"IETSI-ESSALUD (2024, May 02). An\u00e1lisis de Impacto Presupuestal de Esquemas Combinados de Ant\u00a1v\u00a1rales de Acci\u00f3n D\u00a1recta Para El Tratamiento de Infecci\u00f3n Cr\u00f3nica Por El Virus de Hepatitis C. Available online: http:\/\/www.essalud.gob.pe\/ietsi\/pdfs\/guias\/hepatitis_c.pdf."},{"key":"ref_40","unstructured":"Organizaci\u00f3n Panamericana de la Salud (2024, May 02). Lista de Medicamentos del Fondo Estrat\u00e9gico. Available online: https:\/\/www.paho.org\/es\/node\/58472."},{"key":"ref_41","unstructured":"Medecines Patent Pool (2024, May 02). Three Additional Generic Manufacturing Partners Join EFFORTS to increase Access to Generic Hepatitis C Treatment Glecaprevir\/Pibrentasvir. Available online: https:\/\/medicinespatentpool.org\/news-publications-post\/g-p-three-new-sublicensees."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/13\/3867\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:08:18Z","timestamp":1760108898000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/13\/3867"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,30]]},"references-count":41,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["jcm13133867"],"URL":"https:\/\/doi.org\/10.3390\/jcm13133867","relation":{},"ISSN":["2077-0383"],"issn-type":[{"type":"electronic","value":"2077-0383"}],"subject":[],"published":{"date-parts":[[2024,6,30]]}}}